Skin cancer kills by spreading from the skin into vital organs, where it disrupts their ability to function. A mole or lesion that starts on the surface can send cancer cells through the lymphatic system and bloodstream to the lungs, brain, liver, and bones. Once those organs fail, the cancer becomes fatal. About 83% of melanomas are caught early, when the five-year survival rate sits at 97.6%. But when melanoma reaches distant organs, that number drops to 16.2%.
How Cancer Cells Leave the Skin
Skin cancer doesn’t stay on the surface forever if left untreated. As a tumor grows deeper, it eventually reaches the lymphatic vessels beneath the skin. These vessels are lined with cells that have frequent gaps and no strong barrier, making them relatively easy for cancer cells to enter compared to blood vessels. Once inside, tumor cells travel through the lymphatic system to nearby lymph nodes, and from there into general blood circulation.
The cancer cells aren’t just drifting passively. Melanoma cells carry surface receptors that respond to chemical signals produced by lymph nodes and lymphatic vessels, essentially following a trail toward the places where they’ll set up new tumors. The primary tumor also stimulates the growth of new lymphatic vessels around itself, creating more entry points. This is why a thicker, deeper tumor is so much more dangerous: it has had more time to build these escape routes.
Tumor Depth Is the Critical Measurement
The single most important factor in whether a melanoma will kill you is how deep it has grown into the skin, measured in millimeters. A depth of 0.8 mm is the threshold that separates lower-risk tumors from higher-risk ones. Below that line, the cancer is almost always curable with surgery alone. Above it, the odds of spread increase progressively with each additional millimeter of depth.
Tumors thicker than 4.0 mm carry significantly worse survival rates. Interestingly, once a melanoma exceeds about 15 mm in thickness, the relationship between depth and survival flattens out, likely because at that point the cancer has almost certainly already spread regardless of exact size. This is why early detection matters so much: catching a melanoma when it’s still thin changes the outcome dramatically.
What Happens When It Reaches the Lungs
Respiratory failure is the most common cause of death in advanced melanoma, accounting for about 22% of deaths. When cancer cells settle in the lungs, they form tumors that replace healthy tissue and interfere with oxygen exchange. Fluid can also build up between the chest wall and the lung, a condition called pleural effusion, which compresses the lung and makes breathing progressively harder.
The symptoms often start subtly: a persistent cough, mild breathlessness during activity, occasionally coughing up blood. As the tumors grow or fluid accumulates, breathing becomes difficult even at rest. Patients with cancer that has spread to the lining around the lungs are more than twice as likely to die from respiratory failure.
What Happens When It Reaches the Brain
Brain metastases cause about 9% of deaths in advanced melanoma. Tumors in the brain create pressure inside the skull, damage surrounding tissue, and disrupt normal neurological function. The symptoms depend on where the tumors land: memory problems, personality changes, confusion, severe headaches with nausea, seizures, or weakness in an arm or leg. Because the skull is a fixed, closed space, even small tumors can cause serious symptoms by pressing on critical structures.
What Happens When It Reaches the Liver
Liver failure accounts for roughly 9% of deaths. The liver filters blood and processes toxins, so when cancer replaces enough liver tissue, waste products build up in the body. This causes yellowing of the skin and eyes, intense itching, nausea, loss of appetite, and fluid collecting in the abdomen. Pain or discomfort on the right side of the abdomen is often the first sign. As liver function declines, confusion and drowsiness follow because the brain is affected by the toxins the liver can no longer clear.
Bone and Bowel Involvement
Cancer that reaches the bones causes a continuous, gnawing pain that doesn’t improve with rest. It weakens bones to the point where they fracture easily and can release excess calcium into the blood, leading to dehydration, confusion, and nausea. When cancer settles in the spine, it can compress the spinal cord, potentially causing leg weakness, numbness, paralysis, and loss of bladder and bowel control.
Melanoma can also spread to the small bowel, causing abdominal pain, nausea, weight loss, and anemia. In some cases, tumors press on or block the intestine, creating a surgical emergency.
Warning Signs That Cancer Has Spread
Before organ-specific symptoms appear, metastatic skin cancer often announces itself through general changes: hard or swollen lymph nodes, unexplained weight loss, persistent fatigue, or a hard lump on the skin away from the original site. Swollen lymph nodes in the armpit, groin, or neck can block fluid drainage, causing noticeable swelling in the nearby arm, leg, or face.
These signs don’t always mean cancer has spread, but they warrant prompt evaluation, especially in someone with a history of melanoma or an existing suspicious lesion.
Non-Melanoma Skin Cancers Can Be Fatal Too
Melanoma gets the most attention, but squamous cell carcinoma (the second most common skin cancer) can also kill. The risk factors that make it deadly are specific: tumors 4 cm or larger, invasion deep beyond the fat layer under the skin, and growth along nerves. A tumor 4 cm or larger carries 4.5 times the risk of death compared to a smaller one, and nerve involvement nearly triples the risk.
Patients with none of these high-risk features had a 100% three-year disease-specific survival rate. Those with at least one risk factor dropped to 70%. So while most squamous cell carcinomas are easily treated, certain aggressive ones follow the same deadly pattern as melanoma, spreading to lymph nodes and distant organs.
Merkel cell carcinoma, a rare skin cancer, is even more aggressive. Patients with Merkel cell carcinoma are 2.3 times more likely to die from their cancer than patients with melanoma at similar stages.
How Treatment Has Changed the Odds
Until about 2011, a diagnosis of stage IV melanoma was almost uniformly fatal. The introduction of immunotherapy drugs that help the immune system recognize and attack cancer cells has substantially changed outcomes. Among patients who receive these treatments, one-year survival has improved by roughly 28 to 30%. A ten-year follow-up of one major immunotherapy drug showed a 29% reduction in overall mortality compared to older treatments.
The survival statistics by stage tell the full story of why timing matters. Melanoma caught at stage 0 (confined to the outermost skin layer) has a 100% five-year survival rate. Localized melanoma (stages I and II) sits at 97.6%. Once it reaches nearby lymph nodes (stage III), survival drops to 60.3%. At stage IV, with distant organ involvement, it falls to 16.2%. Across all stages combined, the overall five-year survival rate is 90.5%, largely because the vast majority of cases are caught early.
The gap between 97.6% and 16.2% is the clearest illustration of how skin cancer kills: not by what it does on the skin, but by what it does once it leaves it.